Merrill keeps Actelion at neutral

Actelion was retained at neutral by Merrill Lynch analyst Erica Whittaker after the company's second-quarter results surpassed the analyst's and consensus expectations. Net revenues were CHF 227 million, compared to Merrill's estimate of CHF 212 million and consensus of CHF 212 million. Adjusted earnings per share were CHF 2.27, versus the analyst's forecast of CHF 1.98. Actelion now expects total net revenues of CHF 880 million to CHF 910 million, up from previous guidance of CHF 840 million to CHF 860 million. Shares of the Allschwil, Switzerland-based pharmaceutical company were up CHF 7.40, or 5.69%, at CHF 137.40 on volume of 420,662 shares versus the three-month running average of 159,867 shares. (Swiss: ATLN SW)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.